Biodesix Buys US Laboratory Assets From Oncimmune
Executive Summary
Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.
You may also be interested in...
Oncimmune Expands Application Of Liquid Biopsy Auto-Antibody Technology
The company’s liquid biopsy test business is complemented by a patient-stratification service for pharmaceutical companies.
Breakthrough Status, Big Investments For Liquid Biopsies
The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.